Accéder au contenu
Merck

Lassa hemorrhagic shock syndrome-on-a-chip.

Biotechnology and bioengineering (2020-11-27)
Huaqi Tang, Yasmine Abouleila, Alireza Mashaghi
RÉSUMÉ

Lack of experimental human models hinders research on Lassa hemorrhagic fever and the development of treatment strategies. Here, we report the first chip-based model for Lassa hemorrhagic syndrome. The chip features a microvessel interfacing collagen network as a simple mimic for extracellular matrix, allowing for quantitative and real-time vascular integrity assessment. Luminal infusion of Lassa virus-like particles led to a dramatic increase in vascular permeability in a viral load-dependent manner. Using this platform, we showed that Fibrin-derived peptide FX06 can be used to suppress the vascular integrity loss. This simple chip-based model proved promising in the assessment of disease severity and provides an easy-to-use platform for future investigation of Lassa pathogenesis and drug development in a human-like setting.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Albumine de sérum bovin, heat shock fraction, pH 7, ≥98%
Sigma-Aldrich
Bicarbonate de sodium, powder, BioReagent, for molecular biology, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Triton X-100, for molecular biology
Sigma-Aldrich
Phalloïdine-isothiocyanate de tétraméthylrhodamine B, sequence from Amanita phalloides(synthetic: peptide sequence)